Selective serotonin reuptake inhibitors in the treatment of social phobia: The emerging gold standard

CNS Drugs

Volumn 11, Issue 4, 1999, Pages 307-315

  Van Ameringen, Michael ^a,d   Mancini, Catherine ^a   Oakman, Jonathan M ^b   Farvolden, Peter ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF WATERLOO   (Canada)

^c HAMILTON HEALTH SCIENCES   (Canada)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; BUSPIRONE; CITALOPRAM; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; ONDANSETRON; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; HUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIAL PHOBIA; TREATMENT OUTCOME;

EID: 0032893993     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199911040-00006     Document Type: Review

References (51)

1. 1. American Psychiatrie Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
2. 2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. rev. Washington, DC; American Psychiatric Press, 1987
3. 3. Robins L, Helyer JE, Weissman MM, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949-58
4. 4. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychol 1994; 151: 408-12
5. 5. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
6. 6. Rapee RM, Sanderson WC, Barlow DH. Social phobia features across DSM-III-R anxiety disorders. J Psychopathol Behav Assessment 1988; 10; 287-99
7. 7. Schneier FR, Johnson J, Hornig CD, et al. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992; 49: 282-8
8. 8. Stein MB, Tancer ME, Gelernter CS, et al. Major depression in patients with social phobia. Am J Psychol 1990; 147: 637-9
9. 9. Van Ameringen M, Mancini C, Styan G, et al. Relationship of social phobia and other psychiatric illness. J Affect Disord 1991; 21: 93-9
10. 10. Liebowitz MR, Gorman JM, Fyer AJ, et al. Social phobia: review of a neglected anxiety disorder. Arch Gen Psvchiatry 1985; 42: 729-36
11. 11. Van Ameringen M, Mancini C, Wilson C, et al. The prevalence of school dropouts in an anxiety disorders clinic [abstract]. 148th meeting of the American Psychiatric Association, 1995 May 20-25; Miami (FL), 155-6
12. 12. Tanser ME, Uhde TW. Social phobia: a review of pharmacological treatment. CNS Drugs 1995; 3 (4): 267-78
13. 13. Heimberg RG, Juster HR. Cognitive behavioural treatments: literature review. In: Heimberg RG, Liebowitz MR, Hope DA, et al. editors. Social phobia: diagnosis assessment and treatment. New York: Guilford Press, 1995: 261-309
14. 14. Liebowitz MR, Schneier P, Campeas R, et al. Phenelzine vs atenolol in social phobia: a placebo controlled trial. Arch Gen Psychiatry 1992; 49: 290-300
15. 15. Versiani M, Nardi AE, Mundion FD, et al. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992; 161: 353-60
16. 16. The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia: a double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 71-80
17. 17. Schneier FR, Goetz D, Campeas BF, et al. Placebo controlled trial of moclobemide in social phobia. Br J Psychiatry 1998; 172: 70-7
18. 18. Noyes R, Moroz G, Davidson JR, et al. Moclobemide in social phohia: a controlled dose-response trial. J Clin Psychopharmacol 1997; 17: 247-54
19. 19. van Vliet LM, Den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine a selective MOA-A inhibitor. Eur Neuropsychopharmacol 1992; 2: 21-9
20. 20. Lott M, Greist JH, Jefferson JW, et al. Brofaromine for social phohia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 1997, 17: 255-60
21. 21. Fahlen T, Nilsson HL, Borg K, et al. Social phobia: the clinical efficacy and toleranilitv of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine: a double-blind placebo-controlled study. Acta Psychiatr Scand 1995; 92: 351-8
22. 22. Gelernter CS, Uhde TW, Cimbolic P, et al. Cognitive-behavioral and pharmacological treatments of social phobia: a controlled study. Arch Gen Psychiatry 1991; 48: 938-45
23. 23. Davidson JRT, Potts NS, Richichi F., et al. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993; 13:423-8
24. 3 antagonist, ondansetron, in social phobia [abstract]. 33rd Annual Meeting of the American College of Neuropsychopharmacology: 1994 Dec 12-16; San Juan, Puerto Rico
25. 25. Humble M, Fahalen T, Koezkas C, et al. Social phobia: efficacy of brofaromine versus placebo [abstract]. In: New research program and abstracts of the 145th Annual Meeting of the American Psychiatric Association: 1992 May 6; Washington, 11
26. 26. Clark DB, Agras WS. The assessment and treatment of performance anxiety m musicians. Am J Psychiatry 1991; 148: 598-605
27. 27. van Vliet IM. den Boer JA, Westenberg HGM, et al. Clinical effects of buspirone in social phobia: adouble-blind placebo-controlled study. J Clin Psychiatry 1997; 58 (4): 164-8
28. 28. van Vliet LM. Den Boer J, Westenberg HGM. Psychopharmacological treatment of social phobia: a double-blind placebo controlled study with fluvoxamme. Psychopharmacology 1994; 115: 128-34
29. 29. Katzelnick DJ, Kobak KA, Greist JH, et al. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995; 152: 1368-71
30. 30. Stein M, Liebowitz M, Lydiard B, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder). JAMA 1998; 280 (8): 708-13
31. 31. Van Ameringen M, Mancini C, Oakman J. Nefazodone in the treatment of social phobia. J Clin Psychiatry 1999 Feb; 60 (2): 96-100
32. 32. Sternbach H. Fluoxetine treatment of social phobia. J Clin Psychopharmacol 1990; 10(3): 230-1
33. 33. Schneier FR, Chin SJ, Hollander E, et al. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992; 12(1): 62-3
34. 34. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [letter]. J Clin Psychopharmacol 1992; 12 (4): 293-5
35. 35. First MB, Spitzer RL, Gibbon, M, et al. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCTD I/P, version 2.0). New York, NY: Biometrics Research Department, New York State Psychiatric Institute, 1995
36. 36. Van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993; 54 (1): 27-32
37. 37. Van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994; 31: 141-5
38. 38. Munjack DJ, Flowers C, Eagan TV. Sertraline in social phobia. Anxiety 1994/1995; 1: 196-8
39. 39. Czepowicz VD, Johnson MR, Lydiard RB, et al. Sertraline in social phobia [letter]. J Clin Psychopharmacol 1995; 15 (5): 372-3
40. 40. Mancini C, Van Ameringen M. Paroxetine in social phobia. J Clin Psychiatry 1996; 57 ( 11 ): 519-22
41. 41 Stein M, Chartier MJ, Hazen AL, et al. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996; 16(3): 218-22
42. 42. Lepola U, Koponen H, Leinonen E. Citalopram in the treatment of social phobia: a report of three cases. Pharmacopsychiatry 1994; 27: 186-8
43. 43. Bouwer C, Stein DJ. Use of the selective serotonin reuptake inhibitor citalopram in the treatment of generalized social phobia. J Affect Disord 1998; 49: 79-82
44. 44. Liebowitz MR. Social phobia. In: Ban TA, Pichot P, Poldinger W, editors. Modern problems of pharmacopsychiatry. Vol 22. Basel, Switzerland: Karger, 1987: 141-73
45. 45. Van Ameringen MA, Bowen RC, Chokka PR, et al. Sertraline treatment of social phobia: a 20-week, double-blind, placebo-controlled study. Presented at the 37th Annual Meeting of the American College of Neuropsyopharmacology: 1998 Dec 14-18; San Juan, Puerto Rico
46. 46. Stein MB, Fyer AJ, Davidson JRT, et al. Fluvoxamine in the treatment of social phobia: a double-blind, placebo-controlled study. Am J Psychiatry. In press
47. 47. Davidson JRT, Potts NLS, Richiehi EA, et al. The Brief Social Phobia Scale. J Clin Psychiatry 1991; 52 (11 Suppl.): 48-51
48. 48. Sheehan DV. The anxiety disease. New York, NY: Scribner, 1983
49. 49. Liebowitz, MR, Gorman JM, Fyer AJ, et al. Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988; 49: 252-7
50. 50. Marks IM, Matthews AM. Brief standard self-rating for phobic-patients. Behav Res Ther 1979; 17: 263-7
51. 51. Liebowitz MR. Comparison of pharmacological and cognitive behavioural treatment of social phobia [abstract], 18th National Conference of the Anxiety Disorders Association: 1998 Mar 28; Boston (MA)